EYPT
EyePoint, Inc.
$13.03
+4.24%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$576.5M
Inst. Activity16 buys / 4 sells
Insider Activity1B / 1S
Insider Net $-$16.8K
SEC Reports4
Press Releases3
Recent Activity
Jun 11, 2026
short_volume
Short Volume: EYPT — 85.4% short (0.5M / 0.5M)
Short: 466,052 | Exempt: 0 | TRF Vol: 545,739 | Short Ratio: 85.4% | Off-exchange volume (dark pool
May 25, 2026
Insider
Elston George acquired via exercise 7,500 shares
Chief Financial Officer
May 25, 2026
Insider
Elston George surrendered for taxes 3,627 shares
Chief Financial Officer @ $12.93 ($46.9K)
May 14, 2026
SEC
EyePoint announced its third consecutive positive recommendation from the independent Data Safety Monitoring Committee (
8-K — Impact 6/10
May 14, 2026
Press
EyePoint announced that the independent DSMC completed its third scheduled review of the Phase 3 DURAVYU program for wet
Impact 7/10
Apr 17, 2026
SEC
Ramiro Ribeiro, an officer of EyePoint, Inc., filed a Form 144 to notify intent to sell 9,750 shares of common stock, re
144 — Impact 3/10
Apr 17, 2026
Insider
Ribeiro Ramiro sold 2,437 shares
Chief Medical Officer @ $15.00 ($36.6K)
Apr 13, 2026
SEC
EyePoint, Inc. updated its investor presentation, highlighting positive clinical data for DURAVYU in wet AMD and DME, up
8-K — Impact 3/10
Price Targets
$37.00
+184.0% upside
Strong Buy
Current $13.03
Low $20.00
Median $34.00
High $68.00
12 analysts
$20.00
$68.00
Analyst Ratings
6Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Mar 9, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 4, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.95 ▼ -3.1% | $-1.20 — $-0.77 | -12% YoY | 10 |
| Next Q | $-0.80 ▼ -0.6% | $-1.03 — $-0.46 | 6% YoY | 10 |
| Current FY | $-3.51 ▼ -1.2% | $-4.09 — $-2.69 | -11% YoY | 10 |
| Next FY | $-2.82 ▲ +0.5% | $-4.60 — $-0.83 | 20% YoY | 10 |
Latest Reports
BULLISH
8-K
6/10
EyePoint announced its third consecutive positive recommendation from the independent Data Safety Monitoring Committee (
May 14, 2026
BULLISH
Press
7/10
EyePoint announced that the independent DSMC completed its third scheduled review of the Phase 3 DURAVYU program for wet
May 14, 2026
NEUTRAL
144
3/10
Ramiro Ribeiro, an officer of EyePoint, Inc., filed a Form 144 to notify intent to sell 9,750 shares of common stock, re
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $92.5M | ADD |
| FEDERATED HERMES, INC. | $73.1M | ADD |
| FRANKLIN RESOURCES INC | $65.1M | — |
| JANUS HENDERSON GROUP PLC | $46.4M | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | $45.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 25, 2026 | Elston George | M | $0.00 |
| May 25, 2026 | Elston George | F | $46.9K |
| Apr 17, 2026 | Ribeiro Ramiro | SELL | $36.6K |
| Apr 17, 2026 | Ribeiro Ramiro | M | $20.1K |
| Mar 23, 2026 | Duker Jay | J | $459.4K |
50 institutional holders with $576.5M total value (44,711,725 shares) as of 2026-Q1. Top holders: BlackRock,, FEDERATED, FRANKLIN. Net buying activity: 16 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7,177,337 | $92.5M | 16.0% | ADD +36.7% |
| 2 | FEDERATED HERMES, INC. | 5,669,589 | $73.1M | 12.7% | ADD +36.3% |
| 3 | FRANKLIN RESOURCES INC | 5,048,598 | $65.1M | 11.3% | — |
| 4 | JANUS HENDERSON GROUP PLC | 3,601,168 | $46.4M | 8.1% | NEW |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,559,569 | $45.9M | 8.0% | — |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,300,000 | $42.5M | 7.4% | TRIM -29.8% |
| 7 | STATE STREET CORP | 2,097,202 | $27.0M | 4.7% | — |
| 8 | CITADEL ADVISORS LLC | 1,905,875 | $24.6M | 4.3% | — |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 1,438,737 | $18.5M | 3.2% | DOUBLED +141.6% |
| 10 | MORGAN STANLEY | 1,096,109 | $14.1M | 2.5% | DOUBLED +390.0% |
| 11 | HSBC HOLDINGS PLC | 833,455 | $10.7M | 1.9% | NEW |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 793,870 | $10.2M | 1.8% | — |
| 13 | GOLDMAN SACHS GROUP INC | 699,706 | $9.0M | 1.6% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 640,123 | $8.3M | 1.4% | DOUBLED +180.0% |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 570,200 | $7.3M | 1.3% | — |
| 16 | Alyeska Investment Group, L.P. | 509,403 | $6.6M | 1.1% | TRIM -35.1% |
| 17 | VANGUARD FIDUCIARY TRUST CO | 504,472 | $6.5M | 1.1% | — |
| 18 | ExodusPoint Capital Management, LP | 458,102 | $5.9M | 1.0% | — |
| 19 | TWO SIGMA INVESTMENTS, LP | 430,315 | $5.5M | 1.0% | — |
| 20 | AMERIPRISE FINANCIAL INC | 423,262 | $5.5M | 0.9% | ADD +98.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 4,700,000 | 3,300,000 | -29.8% | $42.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 595,392 | 1,438,737 | +141.6% | $18.5M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 223,699 | 1,096,109 | +390.0% | $14.1M | 2026-Q1 |
| HSBC HOLDINGS PLC | NEW | — | 833,455 | — | $10.7M | 2026-Q1 |
| Alyeska Investment Group, L.P. | TRIM | 784,403 | 509,403 | -35.1% | $6.6M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 213,301 | 423,262 | +98.4% | $5.5M | 2026-Q1 |
| Nuveen, LLC | ADD | 181,256 | 260,276 | +43.6% | $3.4M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 188,199 | 258,942 | +37.6% | $3.3M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 168,382 | 218,550 | +29.8% | $2.6M | 2026-Q1 |
| Invesco Ltd. | TRIM | 339,004 | 131,941 | -61.1% | $1.7M | 2026-Q1 |
| FMR LLC | DOUBLED | 19,168 | 129,438 | +575.3% | $1.7M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | DOUBLED | 60,317 | 126,705 | +110.1% | $1.6M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 61,600 | 117,300 | +90.4% | $1.5M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 5,968 | 71,631 | +1100.3% | $923.3K | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 6,739 | 53,117 | +688.2% | $684.7K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 28,820 | 50,506 | +75.2% | $651.0K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 22,775 | 36,072 | +58.4% | $465.0K | 2026-Q1 |
| Baird Financial Group, Inc. | ADD | 17,518 | 28,119 | +60.5% | $362.5K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 1,233 | 2,163 | +75.4% | $27.9K | 2026-Q1 |
| Centiva Capital, LP | NEAR_EXIT | 75,000 | 216 | -99.7% | $2.8K | 2026-Q1 |
| BlackRock, Inc. | ADD | 4,964,526 | 6,787,872 | +36.7% | $124.0M | 2025-Q4 |
| FEDERATED HERMES, INC. | ADD | 4,416,332 | 6,017,433 | +36.3% | $109.9M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 3,794,516 | 4,822,139 | +27.1% | $88.1M | 2025-Q4 |
| JANUS HENDERSON GROUP PLC | NEW | — | 2,937,729 | — | $53.7M | 2025-Q4 |
| Alyeska Investment Group, L.P. | DOUBLED | 201,348 | 784,403 | +289.6% | $14.3M | 2025-Q4 |
3 unique insiders with 9 transactions. Net insider value: -$16.8K ($19.7K bought, $36.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 25, 2026 | Elston George | Chief Financial Officer | EXERCISE | 7,500 | — | — |
| May 25, 2026 | Elston George | Chief Financial Officer | TAX W/H | 3,627 | $12.93 | $46.9K |
| Apr 17, 2026 | Ribeiro Ramiro | Chief Medical Officer | SELL | 2,437 | $15.00 | $36.6K |
| Apr 17, 2026 | Ribeiro Ramiro | Chief Medical Officer | EXERCISE | 2,437 | $8.26 | $20.1K |
| Mar 23, 2026 | Duker Jay S. | President and CEO | J | 52,500 | $8.75 | $459.4K |
| Mar 23, 2026 | Duker Jay S. | President and CEO | J | 76,766 | $13.11 | $1.0M |
| Mar 16, 2026 | Duker Jay S. | President and CEO | BUY | 1,500 | $13.15 | $19.7K |
| Mar 4, 2026 | Ribeiro Ramiro | Chief Medical Officer | EXERCISE | 2,438 | $8.26 | $20.1K |
| Mar 2, 2026 | Elston George | Chief Financial Officer | GIFT | 5,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
BULLISH
8-K
6/10
EyePoint announced its third consecutive positive recommendation from the independent Data Safety Mo
May 14, 2026
NEUTRAL
144
3/10
Ramiro Ribeiro, an officer of EyePoint, Inc., filed a Form 144 to notify intent to sell 9,750 shares
Apr 17, 2026
NEUTRAL
8-K
3/10
EyePoint, Inc. updated its investor presentation, highlighting positive clinical data for DURAVYU in
Apr 13, 2026
NEUTRAL
INST-CLUSTER
4/10
Three mega-passive institutions — Wells Fargo, Schwab, and UBS — increased their holdings in EyePoin
Feb 28, 2026
BULLISH
7/10
EyePoint announced that the independent DSMC completed its third scheduled review of the Phase 3 DUR
May 14, 2026
MIXED
6/10
EyePoint reported a significant year-over-year decline in revenue and increased losses for Q4 and fu
Mar 4, 2026
NEUTRAL
5/10
EyePoint, Inc. announced the first patient dosed in both Phase 3 COMO and CAPRI trials for DURAVYU (
Mar 2, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 18 analysts: 6 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$37.00 mean target
+184.0% upside
Strong Buy (1.25)
$20.00 Low
$68.00 High
| Metric | Value |
|---|---|
| Current Price | $13.03 |
| Target Low | $20.00 |
| Target Mean | $37.00 |
| Target Median | $34.00 |
| Target High | $68.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.95 | $-1.20 | $-0.77 | -11.5% | -3.1% | 1↑ 8↓ | $0.0B | -93.1% | 10 |
| Next Q 2026-09-30 |
$-0.80 | $-1.03 | $-0.46 | 5.5% | -0.6% | 3↑ 5↓ | $0.0B | -66.7% | 10 |
| Current FY 2026-12-31 |
$-3.51 | $-4.09 | $-2.69 | -10.8% | -1.2% | 2↑ 7↓ | $0.0B | -94.6% | 10 |
| Next FY 2027-12-31 |
$-2.82 | $-4.60 | $-0.83 | 19.6% | +0.5% | 3↑ 5↓ | $0.1B | 2888.0% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.948 | |
| 7d ago | $-0.948 | |
| 30d ago | $-0.919 | -0.029 |
| 60d ago | $-0.833 | -0.115 |
| 90d ago | $-0.839 | -0.109 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
short_volume
Short Volume: EYPT — 85.4% short (0.5M / 0.5M)
Short: 466,052 | Exempt: 0 | TRF Vol: 545,739 | Short Ratio: 85.4% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: EYPT — 66.3% short (0.6M / 0.9M)
Short: 575,009 | Exempt: 2,600 | TRF Vol: 867,754 | Short Ratio: 66.3% | Off-exchange volume (dark pool + OTC)
May 19, 2026
other
EyePoint Announces Participation at Upcoming Investor Conferences
<p>WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovativ
May 18, 2026
Clinical Trial
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: EYP-1901 (Phase 3)
Trial: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
May 14, 2026
fda
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
<p align="center"><em>– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – </em><br></p>
May 12, 2026
clinical_trial_readout
T-90d Trial Readout: EYP-1901 (Phase 3)
Trial: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
May 6, 2026
earnings
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
<p>WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovativ
May 6, 2026
earnings_calendar
EYPT Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings_calendar
EYPT Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: EYP-1901 (Phase 3)
Trial: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: EYP-1901 (Phase 3)
Trial: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Apr 29, 2026
earnings
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
<p>WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovat
Apr 21, 2026
short_volume
Short Volume: EYPT — 60.6% short (0.4M / 0.7M)
Short: 422,033 | Exempt: 0 | TRF Vol: 696,427 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
other
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
<p align="justify">WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commerc
Mar 16, 2026
other
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
<p align="justify">WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commerci